Table 1

CAN MEDICATION CURE OBESITY IN CHILDREN?

Mirano uses a table to summarize the findings presented in two sources.

Effectiveness of Sibutramine and Orlistat in Adolescents

6

	-			
Medication	Subjects	Treatment ^a	Side effects	Average weight loss/gain
Sibutramine	Control	0-6 mos.: placebo	Mos. 6-12: increased blood	After 6 mos.: loss of 3.2 kg (7 lb)
		6-12 mos.: sibutramine	pressure; increased pulse rate	After 12 mos.: loss of 4.5 kg (9.9 lb)
	Medicated	0-12 mos.: sibutramine	Increased blood pressure; increased	After 6 mos.: loss of 7.8 kg (17.2 lb)
			pulse rate	After 12 mos.: loss of 7.0 kg (15.4 lb)
Orlistat	Control	0-12 mos.: placebo	None	Gain of 0.67 kg (1.5 lb)
	Medicated	0-12 mos.: orlistat	Oily spotting; flatulence; abdominal discomfort	Loss of 1.3 kg (2.9 lb)

A note gives the source of the data.

A content note explains data common to all subjects.

ne data.	Note. The data on sibutramine are adapted from "Behavior Therapy
	and Sibutramine for the Treatment of Adolescent Obesity," by
	R. I. Berkowitz, T. A. Wadden, A. M. Tershakovec, & J. L. Cronquist,
	2003, Journal of the American Medical Association, 289, pp. 1807-
	1809. The data on orlistat are adapted from Xenical (Orlistat)
	Capsules: Complete Product Information, by Roche Laboratories,
	December 2003, retrieved from http://www.rocheusa.com
	/products/xenical/pi.pdf
	^a The medication and/or placebo were combined with behavioral
	therapy in all groups over all time periods.

Source: Hacker/Sommers (Boston: Bedford/St. Martin's, 2011, 2006).

This sample follows the style guidelines in the Publication Manual of the American Psychological Association, 6th ed. (2010).